The first article of this series argued that the peptide boom is not just a fringe fad but a parallel ecosystem, built by people who feel conventional medicine is too slow, too narrow, or too inaccessible for the goals they care about. In our second article, we asked how far bodily autonomy should extend when …
Continue reading “The Peptide Paradox (3): When the System Has No Middle Ground”
The gray‑market peptide boom is no longer a fringe curiosity. It has become a growing parallel ecosystem for people who feel conventional medicine is too slow, too restrictive, too expensive, and often not designed for the kinds of outcomes they care about. In this three‑part series we examine that ecosystem: how mistrust of institutions is …
Continue reading “The Peptide Paradox (1): When Institutional Distrust Drives Alternative Science”
Chronic insomnia affects millions of people, and it’s far more than just a frustrating night or two without sleep. For those who experience it, insomnia becomes a relentless cycle: the desperation to sleep intensifies anxiety, which makes sleep even harder to achieve. This is exactly what happened to my adult son during a particularly stressful …
In our last article, we discussed how “Healthy Aging” is emerging as a new, targeted therapeutic area. Among the most surprising candidates showing promise in this field are glucagon-like peptide-1 receptor agonists (GLP-1 RAs) – medications originally developed to target diabetes. Research into GLP-1 RAs has an interesting history that started back in the early …
Continue reading “Could GLP-1 Receptor Agonists Become the First True “Longevity-Enhancing” Drugs?”